Fruquintinib in Refractory Metastatic Colorectal Cancer: A Real-world Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

520 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-01-01

Study Completion Date

2023-12-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Fruquintinib is an oral tyrosine kinase inhibitor (TKI), which improves progression-free survival (PFS) and overall survival (OS) in patients with refractory metastatic colorectal cancer (mCRC). Here, we explore the real-world treatment patterns of fruquintinib in the third- or late-line setting for mCRC in six centers in China.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Fruquintinib in Patients With Metastatic Colorectal Cancer

NCT02196688

Colorectal Cancer

COMPLETED PHASE2

Fruquintinib as a Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer

NCT04296019

Colo-rectal Cancer

UNKNOWN PHASE2

Real World Study of Regorafenib Versus Fruquintinib in Colorectal Cancer

NCT04431791

Colorectal Cancer

UNKNOWN

Fruquintinib Plus Capecitabine Versus Capecitabine as Maintenance Therapy for Metastatic Colorectal Cancer After First-line Chemotherapy

NCT05451719

Colorectal Cancer Colorectal Cancer Stage IV

UNKNOWN PHASE2

Fruquintinib in the Cross-line Treatment of Refractory mCRC

NCT06099314

Fruquintinib Metastatic Colorectal Cancer

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Cancer Refractory Colorectal Cancer Metastatic Colorectal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

monotherapy group

patients received fruquintinib alone

Fruquintinib

Intervention Type DRUG

an oral tyrosine kinase inhibitor (TKI)

combine group

patients administered fruquintinib in combination with chemotherapy or/and anti-PD1 antibodies

Fruquintinib

Intervention Type DRUG

an oral tyrosine kinase inhibitor (TKI)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fruquintinib

an oral tyrosine kinase inhibitor (TKI)

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

PD1 antibodies chemotherapy drugs

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

(1) histology-confirmed metastatic CRC (mCRC); (2) disease progression on standard therapy with at least two lines of chemotherapy, including fluorouracil, oxaliplatin, and irinotecan with or without biologics such as bevacizumab and cetuximab; (3) fruquintinib administered as salvage treatment; (4) available clinical data.

Exclusion Criteria

(1) lack of follow-up data; (2) fruquintinib administration as second-line treatment; (3) fruquintinib administration stopped after less than two cycles.

Eligible Sex

ALL

Accepts Healthy Volunteers

No